Petra V.
- Country
- Germany
- Department
- --
Research Overview
Data & Insights
Has run more than one trial at 0 of 31 partner sites.
Specializations
Breast Oncology
Focus on hormone‑responsive and HER2‑targeted breast cancer across early, advanced and metastatic settings.
- Hormone receptor‑positive, HER2‑negative breast cancer
- HER2‑positive breast cancer
- Triple‑negative breast cancer
- PIK3CA‑mutated breast cancer
- BRCA‑mutated breast cancer
Investigations include novel antibody‑drug conjugates and pathway‑directed agents for disease control.
Lung Oncology
Engagement in therapeutic development for non‑small cell lung cancer and small‑cell lung cancer, emphasizing driver‑mutation and immunotherapy strategies.
- EGFR‑mutated NSCLC
- KRAS G12C‑mutated NSCLC
- PD‑L1‑high NSCLC
- Squamous NSCLC
- Limited‑stage small‑cell lung cancer
Research addresses resistance mechanisms and combination regimens to improve survival.
Gastro‑esophageal Oncology
Targeted studies on gastric cancer, esophageal adenocarcinoma and gastroesophageal junction adenocarcinoma, including biomarker‑selected cohorts.
- HER2‑expressing gastroesophageal adenocarcinoma
- Claudin‑18.2 positive tumors
- FGFR2b‑positive adenocarcinoma
- Advanced gastric cancer
- Neoadjuvant therapy for resectable esophageal cancer
Efforts aim to integrate targeted agents with peri‑operative treatment.
Gynecologic Oncology
Clinical focus on ovarian cancer, endometrial cancer and related tubo‑peritoneal malignancies, with attention to homologous recombination deficiency and hormonal pathways.
- Platinum‑resistant ovarian cancer
- PARP inhibitor‑pretreated ovarian cancer
- High‑risk endometrial cancer
- FGFR‑altered endometrial carcinoma
- Hormone‑receptor positive, HER2‑negative endometrial cancer
Studies explore maintenance strategies and novel targeted therapies.
Uro‑Oncology and Rare Tumors
Investigation of bladder cancer, urothelial carcinoma and select rare solid tumors, emphasizing molecularly driven approaches.
- Muscle‑invasive bladder cancer
- FGFR‑altered urothelial carcinoma
- High‑risk invasive urothelial carcinoma
- Rare epithelial ovarian tumors
- Peritoneal carcinomatosis
Research includes antibody‑drug conjugates and checkpoint inhibition in these indications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.